Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer

Lin, Chun–Chi; Chen, Te-Hung; Wu, Yu‐Chung; Fang, Chuan-Yin; Wang, Jaw‐Yuan; Chen, Chou-Pin; Huang, Kai‐Wen; Jiang, Jeng‐Kai

doi:10.1245/s10434-020-08914-8

Cited by 7 publications

(9 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer (CRC) is a worldwide malignant disease with a high prevalence, and nearly 9% of cancers are derived from CRC [ 1 , 2 ]. It is the third most common cancer in the world, with a rapidly increasing prevalence [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer

Chen

Tsai

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Locally advanced colon cancer (LACC) is associated with surgical challenges during R0 resection, increased postoperative complications, and unfavorable treatment outcomes. Neoadjuvant concurrent chemoradiotherapy followed by surgical resection is an effective treatment strategy that can increase the complete surgical resection rate and improve the patient survival rate. This study investigated the efficacy and toxicity of concurrent chemoradiotherapy in patients with LACC as well as the prognosis and long-term clinical outcomes of these patients. Materials From January 2012 to July 2020, we retrospectively reviewed the real-world data of 75 patients with LACC who received neoadjuvant concurrent chemoradiotherapy. The chemotherapy regimen consisted of folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX). The following data were obtained from medical records: patients’ characteristics, pathologic results, toxicity, and long-term oncologic outcome. Results Of the 75 patients, 13 (17.3%) had pathologic complete responses. Hematologic adverse effects were the most common (grade 1 anemia: 80.0% and leukopenia: 82.7%). Conversely, grade 2 or 3 adverse effects were relatively uncommon (<10%). Pathologic N downstaging, ypT0, and pathologic complete responses were significant prognostic factors for patient survival. Multivariate analysis revealed that pathologic N downstaging was an independent predictor of patients’ overall survival (P = 0.019). The estimated 5-year overall and disease-free survival rates were 68.6% and 50.6%, and the medians of overall and disease-free survival periods were 72.3 and 58.7 months, respectively. Moreover, patients with pathologic complete responses had improved overall survival (P = 0.039) and an improved local recurrence control rate (P = 0.042) but an unfavorable distant metastasis control rate (P = 0.666) in the long-term follow-up. Conclusion The long-term oncologic outcome of patients with LACC following concurrent chemoradiotherapy is acceptable, and the adverse effects seem to be tolerable. Pathologic N downstaging was an independent prognostic factor for patients’ overall survival. However, a large prospective, randomized control study is required to confirm the current results.

show abstract

Section: Introductionmentioning

confidence: 99%

“…It is the third most common cancer in the world, with a rapidly increasing prevalence [ 2 , 3 ]. In Asia, CRC increases the mortality rate and causes major health problems [ 1 , 4 ]. In Taiwan, CRC is now the most common cancer according to the data from Ministry of Health and Welfare of Taiwan [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer

Chen

Tsai

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…CRC caused approximately 881,000 deaths in 2018 and is the second leading cause of cancer-related deaths worldwide [31]. In Taiwan, CRC incidence has recently increased and is the third leading cause of cancer-related deaths [2,7]. Studies showed that chronic inflammatory lung disease, such as COPD, pneumoconiosis, and chronic rhinosinusitis, increased cancer incidence in Taiwan population-based cohort studies [11,32,33].…”

Section: Discussionmentioning

confidence: 99%

“…Colorectal cancer (CRC) is a common and fatal malignancy, estimated to reach 2.5 million cases worldwide by [1]. In Taiwan, the incidence of CRC has rapidly increased during the past decades (2460 cases in 1988, 6679 cases in 1998, 11,449 cases in 2008, and 16,525 cases in 2018, as analyzed by the Taiwan Cancer Registry (TwCR)) [2]. The clinical presentations of CRC include no symptoms (the majority in the early stage), symptoms caused by the local tumor (bloody stool, abdominal pain, bowel habit change, or irondeficiency anemia) [3], and symptoms from metastatic cancer (liver, lung, bone, brain, etc.)…”

Section: Introductionmentioning

confidence: 99%

“…Asymptomatic patients with CRC diagnosed by screening have a better risk against death, recurrence, survival, and disease-free interval than those not diagnosed by screening [6]. Since 2008, the Ministry of Health and Welfare (MOHW) of Taiwan has started screening for CRC in the Cancer Care Quality Accreditation Program [2]. However, CRC remained the third leading cause of cancer death, leading to 6436 deaths (12.8% of all cancer deaths, 27.3 deaths per 100,000 population) in 2019, according to the MOHW of Taiwan [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Obstructive Pulmonary Disease Increases the Risk of Mortality among Patients with Colorectal Cancer: A Nationwide Population-Based Retrospective Cohort Study

Cheng

Chiang

Peng

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in Taiwan. Chronic obstructive pulmonary disease (COPD) is associated with CRC mortality in several population-based studies. However, this effect of COPD on CRC shows no difference in some studies and remains unclear in Taiwan’s population. Methods: We conducted a retrospective cohort study using Taiwan’s nationwide database. Patients newly diagnosed with CRC were identified from 2007 to 2012 via the Taiwan Cancer Registry dataset and linked to the National Health Insurance research database to obtain their medical records. Propensity score matching (PSM) was applied at a ratio of 1:2 in COPD and non-COPD patients with CRC. The 5-year overall survival (OS) was analyzed using the Cox regression method. Results: This study included 43,249 patients with CRC, reduced to 13,707 patients after PSM. OS was lower in the COPD group than in the non-COPD group. The adjusted hazard ratio (aHR) for COPD was 1.26 (95% confidence interval (CI), 1.19–1.33). Moreover, patients with CRC plus preexisting COPD showed a higher mortality risk in all stage CRC subgroup analysis. Conclusions: In this 5-year retrospective cohort study, patients with CRC and preexisting COPD had a higher mortality risk than those without preexisting COPD, suggesting these patients need more attention during treatment and follow-up.

show abstract

Analysis of reporting quality of clinical practice guidelines/consensuses on metastatic colorectal cancer based on the RIGHT checklist

Liu

et al. 2022

Journal of Healthcare Quality Research

View full text Add to dashboard Cite

Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer

Cited by 7 publications

References 83 publications

Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer

Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer

Chronic Obstructive Pulmonary Disease Increases the Risk of Mortality among Patients with Colorectal Cancer: A Nationwide Population-Based Retrospective Cohort Study

Analysis of reporting quality of clinical practice guidelines/consensuses on metastatic colorectal cancer based on the RIGHT checklist

Contact Info

Product

Resources

About